JOP20220163B1 - مركب بيريدازينيل-ثيازول كربوكساميد - Google Patents

مركب بيريدازينيل-ثيازول كربوكساميد

Info

Publication number
JOP20220163B1
JOP20220163B1 JOJO/P/2022/0163A JOP20220163A JOP20220163B1 JO P20220163 B1 JOP20220163 B1 JO P20220163B1 JO P20220163 A JOP20220163 A JO P20220163A JO P20220163 B1 JOP20220163 B1 JO P20220163B1
Authority
JO
Jordan
Prior art keywords
pyridazinyl
compound
cancer
treatment
cell activation
Prior art date
Application number
JOJO/P/2022/0163A
Other languages
English (en)
Inventor
Nakamura Akihiko
Ikeda Osamu
Kurosawa Kazuo
Miyasaka Kozo
Okuyama Keiichiro
Watanabe Hideyuki
Tomiyama Hiroshi
Iwai Yoshinori
SEKI Yohei
Original Assignee
Astellas Pharma Inc
Kotobuki Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc, Kotobuki Pharmaceutical Co Ltd filed Critical Astellas Pharma Inc
Publication of JOP20220163A1 publication Critical patent/JOP20220163A1/ar
Application granted granted Critical
Publication of JOP20220163B1 publication Critical patent/JOP20220163B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

يزود هذا الاختراع مركب مفيد كمكون نشط في تركيب صيدلاني لعلاج السرطان المرتبط بتنشيط الخلايا المناعية أو السرطان الذي لديه مقاومة للعلاج بالأجسام المضادة لـِ PD-1/الأجسام المضادة لـِ PD-L1. ولقد أجرى المخترعون الحاليون دراسات على مركب مفيد كمكون نشط في تركيب صيدلاني لعلاج السرطان المرتبط بتنشيط الخلايا المناعية أو السرطان الذي لديه مقاومة للعلاج بالأجسام المضادة لـِ PD-1/الأجسام المضادة لـِ PD-L1، ووجدوا أن مركب بيريدازينيل-ثيازول كربوكساميد له تأثير مثبط لـِ DGK ? (DGKzeta)، مما أدى إلى انجاز الاختراع الحالي. ويمكن استخدام مركب بيريدازينيل-ثيازول كربوكساميد وفقاً للاختراع الحالي الذي له تأثير مثبط لـِ DGK ?، كعامل علاجي لعلاج السرطان المرتبط بتنشيط الخلايا المناعية أو السرطان الذي لديه مقاومة للعلاج بالأجسام المضادة لـِ PD-1/الأجسام المضادة لـِ PD-L1.
JOJO/P/2022/0163A 2019-12-25 2022-06-23 مركب بيريدازينيل-ثيازول كربوكساميد JOP20220163B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019233673 2019-12-25
PCT/JP2020/048337 WO2021132422A1 (ja) 2019-12-25 2020-12-24 ピリダジニルチアアゾールカルボキシアミド化合物

Publications (2)

Publication Number Publication Date
JOP20220163A1 JOP20220163A1 (ar) 2023-01-30
JOP20220163B1 true JOP20220163B1 (ar) 2025-10-01

Family

ID=76574296

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2022/0163A JOP20220163B1 (ar) 2019-12-25 2022-06-23 مركب بيريدازينيل-ثيازول كربوكساميد

Country Status (33)

Country Link
US (1) US12227517B2 (ar)
EP (1) EP4083038B1 (ar)
JP (1) JP6948659B1 (ar)
CN (3) CN115626919B (ar)
AR (1) AR120896A1 (ar)
AU (1) AU2020413997B2 (ar)
BR (1) BR112022012637A2 (ar)
CA (1) CA3165889A1 (ar)
CL (1) CL2022001752A1 (ar)
CO (1) CO2022009124A2 (ar)
CR (1) CR20220328A (ar)
DK (1) DK4083038T3 (ar)
DO (1) DOP2022000137A (ar)
EC (1) ECSP22057324A (ar)
ES (1) ES2995459T3 (ar)
FI (1) FI4083038T3 (ar)
HR (1) HRP20241588T1 (ar)
HU (1) HUE069173T2 (ar)
IL (1) IL294136B2 (ar)
JO (1) JOP20220163B1 (ar)
LT (1) LT4083038T (ar)
MX (1) MX2022007993A (ar)
MY (1) MY206825A (ar)
PE (1) PE20230163A1 (ar)
PH (1) PH12022551569A1 (ar)
PL (1) PL4083038T3 (ar)
PT (1) PT4083038T (ar)
SA (1) SA522433129B1 (ar)
SI (1) SI4083038T1 (ar)
TW (1) TWI881008B (ar)
UA (1) UA129628C2 (ar)
WO (1) WO2021132422A1 (ar)
ZA (1) ZA202207543B (ar)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT4081305T (lt) 2019-12-24 2024-11-25 Carna Biosciences, Inc. Diacilglicerolio kinazę moduliuojantys junginiai
AR120896A1 (es) 2019-12-25 2022-03-30 Astellas Pharma Inc COMPUESTO DE PIRIDAZINIL-TIAZOLCARBOXAMIDA COMO INHIBIDORES DE DGKz
PL4139286T3 (pl) 2020-04-24 2025-08-11 Bayer Aktiengesellschaft Podstawione aminotiazole jako inhibitory dgkzeta do aktywacji immunologicznej
AR124172A1 (es) 2020-11-30 2023-02-22 Astellas Pharma Inc Compuesto de heteroarilcarboxamida
CA3222277A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271677A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271659A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
KR20240005901A (ko) 2021-06-23 2024-01-12 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
CN114621214B (zh) * 2022-04-25 2024-04-26 宜春学院 一种抗菌席夫碱n-酰化物及其制备方法和应用
US12600722B2 (en) 2022-07-18 2026-04-14 Incyte Corporation Tetracyclic compounds as DGK inhibitors
US12600723B2 (en) 2022-07-18 2026-04-14 Incyte Corporation Tetracyclic compounds as DGK inhibitors
CN117534665A (zh) * 2022-08-01 2024-02-09 山东轩竹医药科技有限公司 二酰甘油激酶抑制剂
AR131099A1 (es) * 2022-11-18 2025-02-19 Incyte Corp Fluoroalquenos heteroarílicos como inhibidores de dgk
AR131101A1 (es) * 2023-01-12 2025-02-19 Incyte Corp Heteroarilfluoroalquenos como inhibidores de dgk
AR131786A1 (es) 2023-02-06 2025-04-30 Bayer Ag Combinación de anticuerpos ccr8 con inhibidores de dgk
CN120826398A (zh) * 2023-03-30 2025-10-21 微境生物医药科技(上海)有限公司 作为DGKζ抑制剂的化合物
CN120826393A (zh) * 2023-04-06 2025-10-21 微境生物医药科技(上海)有限公司 作为DGKζ抑制剂的噻唑类化合物
WO2025067360A1 (zh) * 2023-09-27 2025-04-03 海思科医药集团股份有限公司 一种DGKzeta拮抗剂及其在医药上的应用
WO2025082460A1 (zh) * 2023-10-20 2025-04-24 上海先祥医药科技有限公司 二酰基甘油激酶抑制剂化合物及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7381401B2 (en) * 2004-01-08 2008-06-03 The University Of Chicago T cell anergy is reversed by active Ras and regulated by diacylglycerol kinase
PL1848435T3 (pl) 2005-01-25 2016-08-31 Synta Pharmaceuticals Corp Związki przeciwko zapaleniom i zastosowania związane z odpornością
CA2639910A1 (en) * 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Thiazole and thiadiazole compounds for inflammation and immune-related uses
JP5182088B2 (ja) * 2006-04-19 2013-04-10 アステラス製薬株式会社 アゾールカルボキサミド誘導体
CA2668210C (en) * 2006-10-31 2013-03-12 Schering Corporation Anilinopiperazine derivatives and methods of use thereof
MX2020002399A (es) 2017-09-06 2020-07-22 Propellon Therapeutics Inc Inhibidores del enlace proteína-proteína de wdr5.
CN112654621B (zh) * 2018-06-27 2024-05-14 百时美施贵宝公司 可作为t细胞活化剂的经取代萘啶酮化合物
AR120896A1 (es) * 2019-12-25 2022-03-30 Astellas Pharma Inc COMPUESTO DE PIRIDAZINIL-TIAZOLCARBOXAMIDA COMO INHIBIDORES DE DGKz
PL4139286T3 (pl) 2020-04-24 2025-08-11 Bayer Aktiengesellschaft Podstawione aminotiazole jako inhibitory dgkzeta do aktywacji immunologicznej
AR124172A1 (es) 2020-11-30 2023-02-22 Astellas Pharma Inc Compuesto de heteroarilcarboxamida

Also Published As

Publication number Publication date
EP4083038A1 (en) 2022-11-02
CN115590854B (zh) 2024-06-07
CN115626919A (zh) 2023-01-20
CN113365994B (zh) 2024-08-09
CN115590854A (zh) 2023-01-13
ZA202207543B (en) 2023-12-20
DOP2022000137A (es) 2022-11-30
AU2020413997B2 (en) 2026-01-08
UA129628C2 (uk) 2025-06-18
AR120896A1 (es) 2022-03-30
BR112022012637A2 (pt) 2022-09-06
JOP20220163A1 (ar) 2023-01-30
CL2022001752A1 (es) 2023-03-10
EP4083038B1 (en) 2024-10-30
PT4083038T (pt) 2024-12-02
CA3165889A1 (en) 2021-07-01
SA522433129B1 (ar) 2024-11-11
IL294136A (en) 2022-08-01
CO2022009124A2 (es) 2022-07-19
US20220315603A1 (en) 2022-10-06
FI4083038T3 (fi) 2024-12-07
CN115626919B (zh) 2025-09-02
JPWO2021132422A1 (ja) 2021-12-23
PE20230163A1 (es) 2023-02-01
TW202136275A (zh) 2021-10-01
TW202413375A (zh) 2024-04-01
TWI881008B (zh) 2025-04-21
DK4083038T3 (da) 2024-12-09
CR20220328A (es) 2022-08-30
MY206825A (en) 2025-01-09
SI4083038T1 (sl) 2025-03-31
IL294136B2 (en) 2025-10-01
US12227517B2 (en) 2025-02-18
JP6948659B1 (ja) 2021-10-13
PH12022551569A1 (en) 2023-11-29
ES2995459T3 (en) 2025-02-10
AU2020413997A1 (en) 2022-06-09
ECSP22057324A (es) 2022-08-31
IL294136B1 (en) 2025-06-01
EP4083038A4 (en) 2023-12-20
PL4083038T3 (pl) 2025-01-27
TW202413376A (zh) 2024-04-01
LT4083038T (lt) 2024-12-27
HRP20241588T1 (hr) 2025-01-31
MX2022007993A (es) 2022-07-21
WO2021132422A1 (ja) 2021-07-01
KR20220119702A (ko) 2022-08-30
CN113365994A (zh) 2021-09-07
HUE069173T2 (hu) 2025-02-28

Similar Documents

Publication Publication Date Title
JOP20220163B1 (ar) مركب بيريدازينيل-ثيازول كربوكساميد
JOP20230118A1 (ar) مركب كربوكساميد أريل غير متجانس
BR112018073920A2 (pt) inibidores de pd-1/pd-l1 para tratamento de câncer".
SA518400356B1 (ar) مثبطات الأرجيناز واستخداماتها العلاجية
MX390954B (es) Composiciones que comprenden una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo.
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
PH12016500575A1 (en) Inhibitors of bruton`s tyrosine kinase
MX383866B (es) Inhibidores de ezh2 para tratar linfomas.
MX375752B (es) Inhibidores de tirosina quinasa de bruton.
EP4684836A3 (en) Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
EA202092456A3 (ru) Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака
AR116121A1 (es) Métodos de tratamiento del cáncer
JOP20180025A1 (ar) مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
BR112022008558A2 (pt) Método de tratamento para câncer, tratamento de combinação de nivolumabe e anticorpos anti-pvrig, e, uso
CY1122968T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει μια ενωση διαμινο-ετεροκυκλικου καρβοξαμιδιου ως δραστικο συστατικο
PH12020550462A1 (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
MX2021010041A (es) Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt.
MX2019009630A (es) Programa de dosificacion de un inhibidor de wnt y una molecula de anticuerpo anti-pd-1 en combinacion.
AU2017258649A1 (en) Covalent BTK inhibitors and uses thereof
MX2019010086A (es) Esquema de dosificacion para una combinacion de ceritinib y una molecula de anticuerpo anti-pd-1.
MX2017013634A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y un polvo.
TW201613926A (en) Inhibitors of bruton's tyrosine kinase
MX387252B (es) EL USO DE DERIVADOS DE QUINOLINONAS QUE TIENE UNA ACTIVIDAD DE INHIBICIÓN DE LA FORMACIÓN DEL COMPLEJO DE C-Myc/Max/ADN EN EL TRATAMIENTO DE CANCER.